Clinical Takeaway
In this rigorous crossover trial, neither a low nor a very high single dose of CBD directly altered cortical excitability or produced measurable sedation in healthy adults. This suggests that CBD’s well-documented benefits in epilepsy syndromes like Dravet and Lennox-Gastaut may depend largely on its interaction with co-administered medications such as clobazam rather than on a standalone brain-quieting effect. Clinicians should keep in mind that CBD’s seizure-reducing properties in these conditions likely reflect pharmacokinetic mechanisms, not direct cortical suppression.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in seizure management stems primarily from pharmacokinetic interactions with concurrent antiepileptic medications like clobazam rather than direct modulation of cortical excitability, which has significant implications for drug selection and combination therapy strategies. Understanding that CBD lacks direct effects on neuronal excitability helps explain variable patient responses and guides more rational polypharmacy decisions in epilepsy treatment, particularly when CBD is used as monotherapy or with non-interacting ASMs. These findings refine our mechanistic understanding of CBD’s therapeutic action and support more evidence-based dosing strategies and drug interaction management in clinical practice.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial challenges a common assumption about cannabidiol’s mechanism of action by demonstrating that CBD does not directly suppress cortical excitability in the way traditional antiepileptic drugs do, suggesting its clinical efficacy in seizure disorders may rely more heavily on pharmacokinetic interactions with co-administered medications like clobazam rather than intrinsic anticonvulsant properties. While this finding is important for mechanistic understanding, clinicians should recognize that the absence of direct cortical effects does not diminish CBD’s proven therapeutic value in Dravet and Lennox-Gastaut syndromes, nor does it explain all of its clinical actions, as drug interactions and other poorly understood pathways may still account for seizure reduction in real-world practice. The study’s controlled laboratory setting may not fully capture the complex pharmacodynamics occurring during long-term polypharmacy in patients with severe epilepsy. Practically speaking, this research reinforces the importance of carefully monitoring CBD’s interactions with concurrent
| |